(CercleFinance.com) – The stock soared nearly +3% as Invest Securities initiated the Buy value with a price target of 5.7E. ‘The title enters our Invest Securities Selection today’.
‘ Although the company remains in its historical field of research which consists of the vectorization of ‘therapeutic genes’ through viral vectors to treat cancer, Transgene today focuses its strategy around 2 state-of-the-art proprietary platforms ‘innovation in the field of precision medicine’ indicates Invest Securities.
The analyst believes that these new technologies mark a turning point in the history of biotech, which is now entering the competition for precision immunotherapy with, in particular, its personalized therapeutic vaccines from the myvac platform, and its armed oncolytic viruses. from the Invi.IO platform that can be administered systemically.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
